Table 3 Screening attendance in the subpopulation with known screening status
|  | Total screening cohort1 (n = 6,125) | Sub-grouped screening cohort according to disease stage2 (n = 5,387) | ||||
|---|---|---|---|---|---|---|
Low-stage subpopulation (n = 3,906) | High-stage subpopulation (n = 1,481) | |||||
Screening attendance326–64 years (yes/no) | ||||||
|  | Cases (n = 1,021) | Controls (n = 5,104) | Low-stage cases (n = 651) | Low-stage controls (n = 2,715) | High-stage cases (n = 247) | High-stage controls (n = 1,234) |
| Â | Â | * | Â | * | ** | * |
 Yes  No | 547 (53.6%) 474 (46.4%) | 3,872 (75.9%) 1,232 (24.1%) | 393 (60.4%) 258 (39.6%) | 2,457 (75.5%) 789 (24.5%) | 88 (35.6%) 159 (64.4%) | 967 (78.4%) 267 (21.6%) |
Screening attendance according to age (yes/no) | ||||||
|  | Cases (n = 821) | Controls (n = 4,106) | Low-stage cases (n = 553) | Low-stage controls (n = 2,765) | High-stage cases (n = 166) | High-stage controls (n = 831) |
Young sub-population (26–49 years) |  | * |  | * | ** | * |
 Yes  No | 446 (54.3%) 375 (45.7%) | 3,129 (76.2%) 977 (23.8%) | 331 (59.9%) 222 (40.1%) | 2,095 (75.8%) 670 (24.2%) | 60 (36.1%) 106 (63.9%) | 654 (78.7%) 177 (21.3%) |
|  | Cases (n = 200) | Controls (n = 998) | Low-stage cases (n = 98) | Low-stage controls (n = 490) | High-stage cases (n = 81) | High-stage controls (n = 403) |
Old sub-population (50–64 years) |  | * |  | * | ** | * |
 Yes  No | 101 (50.5%) 99 (49.5%) | 743 (74.5%) 255 (25.6%) | 62 (63.3%) 36 (36.7%) | 362 (73.9%) 128 (26.1%) | 28 (34.6%) 53 (65.4%) | 313 (77.7%) 90 (22.3%) |